^
    1d
    Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) (clinicaltrials.gov)
    P1, N=16, Completed, Providence Health & Services | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cyclophosphamide • citoplurikin (IRX-2)
    5ms
    NeoIRX: Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Providence Health & Services | Trial completion date: Jun 2025 --> Dec 2025
    Trial completion date
    |
    Keytruda (pembrolizumab) • doxorubicin hydrochloride • cyclophosphamide • citoplurikin (IRX-2)
    6ms
    IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • citoplurikin (IRX-2)
    7ms
    IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=19, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    Imfinzi (durvalumab) • cyclophosphamide • citoplurikin (IRX-2)
    8ms
    IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 (clinicaltrials.gov)
    P2, N=10, Terminated, University of Southern California | Active, not recruiting --> Terminated; Lack of efficacy
    Trial termination
    |
    cyclophosphamide • citoplurikin (IRX-2)
    9ms
    Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Providence Health & Services | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cyclophosphamide • citoplurikin (IRX-2)
    10ms
    IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Dec 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • citoplurikin (IRX-2)
    10ms
    IRX-2 Regimen in Treating Women with Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, University of Southern California | Trial completion date: Nov 2024 --> Aug 2025 | Trial primary completion date: Nov 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • citoplurikin (IRX-2)
    11ms
    IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2024 --> Sep 2025
    Trial completion date
    |
    Imfinzi (durvalumab) • cyclophosphamide • citoplurikin (IRX-2)
    over1year
    Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) (clinicaltrials.gov)
    P1; Trial completion date: May 2024 --> Dec 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    nCounter® PanCancer Immune Profiling Panel
    |
    cyclophosphamide • citoplurikin (IRX-2)
    over1year
    NeoIRX: Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Providence Health & Services | Trial primary completion date: Jun 2024 --> Jul 2023
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • doxorubicin hydrochloride • cyclophosphamide • citoplurikin (IRX-2)
    almost2years
    Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) (clinicaltrials.gov)
    P1; Trial completion date: Jan 2023 --> May 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PD-L1 expression • HER-2 negative
    |
    nCounter® PanCancer Immune Profiling Panel
    |
    cyclophosphamide • citoplurikin (IRX-2)